Bio Protocol has completed a $6.9 million seed round financing, led by Arthur Hayes's Maelstrom Fund

On September 17th, Bio Protocol successfully completed a seed round of financing amounting to $6.9 million, with Arthur Hayes's Maelstrom Fund taking the lead. Other investors involved include Mechanism Capital, Animoca Brands, Zee Prime Capital, Panga Capital, Mirana Ventures, Foresight Ventures, Big Brain Holdings, and others. Bio Protocol is set to launch an AI-based decentralized science platform dedicated to biotech financing and drug discovery. This financing coincides with the launch of Bio V2, which introduces on-chain funding and a decentralized AI-driven framework for early-stage scientific research and development. Researchers, patients, and the crypto community can utilize BioAgents to generate scientific hypotheses, monetize their discoveries, and uncover hidden insights in the field of biology more rapidly than traditional biotech. Bio plans to globally expand the BioAgent framework to other researchers and labs, creating a decentralized scientific machine network to build and monetize biotech research beyond the constraints of traditional pharmaceutical structures. Arthur Hayes expressed that Bio is on the verge of becoming a category-defining launch platform that will fund scientifically appealing research for the community, not just for academia. If successful, this will not only be a launch platform but also mark the emergence of an AI-native research marketplace.